NCT00898924
Completed
Not Applicable
Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106
Alliance for Clinical Trials in Oncology0 sites60 target enrollmentStarted: November 2005Last updated:
ConditionsLung Cancer
Overview
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 60
- Primary Endpoint
- Overall survival
Overview
Brief Summary
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at epidermal growth factor receptor mutations and k-ras oncogene mutations in patients with stage III non-small cell lung cancer.
Detailed Description
OBJECTIVES:
- Determine the frequency of epidermal growth factor receptor (EGFR) and K-ras mutations in patients with stage III non-small cell lung cancer (NSCLC) treated on CALGB 30106.
- Correlate presence or absence of EGFR and/or K-ras mutations with radiographic response to treatment in these patients.
OUTLINE: Tissue samples are analyzed for epidermal growth factor receptor and K-ras mutations.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Overall survival
Time Frame: Up to 3 years
Progression free survival
Time Frame: Up to 3 years
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Not Applicable
Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung CancerLung CancerNCT00899756Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins50
Recruiting
Not Applicable
Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung CancerLung CancerNCT00899405University of California, Davis800
Withdrawn
Not Applicable
Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507Lung CancerNCT00907699Case Comprehensive Cancer Center
Completed
Not Applicable
Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib TosylateLung CancerNCT01124669ECOG-ACRIN Cancer Research Group80
Completed
Not Applicable
Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803Prostate CancerNCT00897351ECOG-ACRIN Cancer Research Group37